Priyankan Datta

Priyankan Datta

Auto-generated profile, based on publicly available information

Priyankan Datta

Department of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA 90089, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in BME Frontiers
Verified
Journal Article
Open access
PDPriyankan Datta
Priyankan Datta
SMSreejesh Moolayadukkam
Sreejesh Moolayadukkam
DCDhrubajyoti Chowdhury
Dhrubajyoti Chowdhury
ARAdnan Rayes
Adnan Rayes
NLNan Sook Lee
Nan Sook Lee
IPIshwar K. Puri
Ishwar K. Puri
Deep-tissue solid cancer treatment has a poor prognosis, resulting in a very low 5-year patient survival rate. The primary challenges facing solid tumor therapies are accessibility, incomplete surgical removal of tumor tissue, the resistance of the hypoxic and heterogeneous tumor microenvironment to chemotherapy and radiation, and suffering caused by off-target toxicities. Here, sonodynamic therapy (SDT) is an evolving therapeutic approach that uses low-intensity ultrasound to target deep-tissue solid tumors. The ability of ultrasound to deliver energy safely and precisely into small deep-tissue (>10 cm) volumes makes SDT more effective than conventional photodynamic therapy. While SDT is currently in phase 1/2 clinical trials for glioblastoma multiforme, its use for other solid cancer treatments, such as breast, pancreatic, liver, and prostate cancer, is still in the preclinical stage, with further investigation required to improve its therapeutic efficacy. This review, therefore, focuses on recent advances in SDT cancer treatments. We describe the interaction between ultrasound and sonosensitizer molecules and the associated energy transfer mechanism to malignant cells, which plays a central role in SDT-mediated cell death. Different sensitizers used in clinical and preclinical trials of various cancer treatments are listed, and the critical ultrasound parameters for SDT are reviewed. We also discuss approaches to improve the efficacies of these sonosensitizers, the role of the 3-dimensional spheroid in vitro investigations, ultrasound-controlled CAR-T cell and SDT-based multimodal therapy, and machine learning for sonosensitizer optimization, which could facilitate clinical translation of SDT.

2 October 2024 in Ultrasonics Sonochemistry
Verified
Journal Article
Open access
PDPriyankan Datta
Priyankan Datta
SMSreejesh Moolayadukkam
Sreejesh Moolayadukkam
RSRakesh Prasad Sahu
Rakesh Prasad Sahu
RGRanjan Ganguly
Ranjan Ganguly
SSSwarnendu Sen
Swarnendu Sen
IPIshwar K. Puri
Ishwar K. Puri
Sonodynamic therapy (SDT) is a minimally invasive targeted cancer therapy that uses focused low-intensity ultrasound (<10 MPa, <10 W/cm2) to activate sonosensitizer drugs. Once activated, these chemical compounds generate reactive oxygen species (ROS) to damage and kill cancer cells. A Phase I clinical trial has shown promising results for treating glioblastoma with SDT. We hypothesize that the efficacy of SDT can be improved by introducing lipid-coated microbubbles that produce a sonochemical effect that enhances ROS production. We investigate the hydrodynamics of a U.S. Food and Drug Administration (FDA)-approved microbubble, Lumason®, and a phospholipid-coated oxygen microbubble to predict the ultrasound parameters that induce sonoluminescence onset in biophysically relevant medium (e.g., water and blood) under clinical SDT conditions. The threshold pressures and frequencies for sonoluminescence with these therapeutic agents lie between 20 kHz - 1 MHz and 0.05 MPa - 1 MPa, respectively. The lipid-coated oxygen microbubble exhibits stronger sonoluminescence than the Lumason® microbubble, suggesting its use for improving SDT efficacy.

31 October 2025 in Nature Materials
Verified
Journal Article
Open access
PDF file
CYChi Woo Yoon
Chi Woo Yoon
CSChunyang Song
Chunyang Song
DNDung Ngo Minh Nguyen
Dung Ngo Minh Nguyen
XYXi Yu
Xi Yu
LZLinshan Zhu
Linshan Zhu
YWYingxiao Wang
Yingxiao Wang
Cell-based cancer immunotherapy holds potential as a therapeutic approach, yet its application for solid tumour treatment remains challenging. Here we report a focused-ultrasound-based approach that mechanically induces the localized expression of CD19 antigen within a subpopulation of cells within solid tumours, which function as local ‘training centres’ to activate chimeric antigen receptor T cells. Activated chimeric antigen receptor T cells attack the whole cancer cell population near the tumour site, thus achieving cancer suppression. The system achieves targeted gene expression by integrating focused-ultrasound-triggered mechanical stimulation and the subsequent calcium response of cancer cells with a doxycycline-gated AND-logic genetic circuit, both of which need to be active for effective induction of CD19 expression. We validate the functionality of the approach in vitro, in organoids and in vivo, achieving direct control of user-designed gene expressions through FUS-mediated mechanical stimulation without the need of any cofactor, demonstrating the approach’s potential as a versatile platform for precisely controllable immunotherapy. Overall, our combinatorial approach offers a focused-ultrasound-controlled remote and non-invasive priming of solid tumours for effective and safe chimeric antigen receptor T cell immunotherapy via the induced production of clinically validated antigens.

21 October 2024 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDPriyankan Datta
Priyankan Datta
NLNan Sook Lee
Nan Sook Lee
SMSreejesh Moolayadukkam
Sreejesh Moolayadukkam
RSRakesh P. Sahu
Rakesh P. Sahu
XYXi Yu
Xi Yu
IPIshwar K. Puri
Ishwar K. Puri
Sonodynamic therapy (SDT) administered using low‐intensity pulsed ultrasound and sonosensitizers is an emerging, minimally invasive, targeted deep‐tissue therapy for solid tumors such as glioblastoma multiforme (GBM). Initial clinical trials show promising outcomes for SDT treatments of GBM. A crucial aspect of SDT is the sonosensitizer that interacts with ultrasound, facilitating energy transfer to the tumor, thus inducing therapeutic efficacy. Current in vitro methods for determining the therapeutic efficacies of sonosensitizers are time‐consuming and expensive. A novel high‐throughput magnetically printed 3D GBM model is used to overcome this challenge. The hypothesis is that the use of two sonosensitizers, one a chemotherapeutic drug, enhances SDT efficacy through their additive chemical interactions. The GBM model is used to evaluate the effectiveness of two sonosensitizer molecules, 5‐aminolevulinic acid (5‐ALA) and theU.S. Food and Drug Administration (FDA)‐approved chemotherapeutic drug Temozolomide (TMZ). It is confirmed that implement high‐throughput GBM models to evaluate sonosensitizer combinations and their efficacies is feasible and, for the first time, show that the combined effect of both sensitizers, 5‐ALA and TMZ, is superior for preventing spheroid growth than employing each molecule separately. This finding is relevant for future clinical trials of GBM treatment with SDT.

12 June 2025 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
DCDhrubajyoti Chowdhury
Dhrubajyoti Chowdhury
SMSreejesh Moolayadukkam
Sreejesh Moolayadukkam
PDPriyankan Datta
Priyankan Datta
IPIshwar K. Puri
Ishwar K. Puri
Implantable medical devices (IMDs) use batteries with toxic electrolytes that can be harmful when leaked and have a limited lifespan, necessitating frequent replacements through painful surgeries. A practical solution is to utilize biocompatible supercapacitors that function with biocompatible electrolytes, making any potential leakages non-toxic and safe while also prolonging device lifespan by incorporating self-powered nanogenerators as their energy source. However, the current biocompatible material-based supercapacitors perform unsatisfactorily with biocompatible electrolytes. In this work, we developed biocompatible MXenes that can work with a biocompatible electrolyte. Two MXenes, with single (Ti3C2Tx) and double (Mo2TiC2Tx) transition metals, are synthesized, and both exhibit biocompatibility with human dermal fibroblast cells. The supercapacitor performance of both MXenes is evaluated in conventional and biocompatible phosphate buffer saline (PBS) electrolyte using cyclic voltammetry, charge–discharge, and electrochemical impedance spectroscopy. Our results reveal that in a three-electrode configuration, Ti3C2Tx outperforms Mo2TiC2Tx due to its high electrochemically active surface area. Furthermore, the device comprising Ti3C2Tx MXene exhibits a high specific capacitance of 87.54 ± 2.88 mF cm−2 and high energy and power densities of 2.97 μW h cm−2 and 500.00 μW cm−2, respectively, which is sufficient to drive IMDs such as pacemakers and neurostimulators. Hence, using MXene supercapacitors in IMDs is proven to be plausible.

12 August 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRudrajit Majumder
Rudrajit Majumder
PDPriyankan Datta
Priyankan Datta
SMSreejesh Moolayadukkam
Sreejesh Moolayadukkam
IPIshwar K. Puri
Ishwar K. Puri
Glioblastoma (GBM) remains a lethal primary brain tumor, in part because therapeutic efficacy is limited by the blood–brain barrier (BBB) and the complex tumor microenvironment (TME). Sonodynamic therapy (SDT), i.e., use of ultrasound to activate chemical sensitizers and generate cytotoxic stress, offers a non-invasive strategy for treating deep-seated intracranial disease, but progress is constrained by the scarcity of validated sonosensitizers and the inefficiency of conventional in vitro screening methods. Here, we introduce a New Approach Methodology (NAM) that couples a neural network-based positive-unlabeled (PU) learning framework with a high-throughput, magnetic field–guided 3D bioprinting platform to accelerate identification and experimental validation of SDT-sensitizing agents. Using curated drug and small-molecule data and RDKit-derived molecular descriptors, the PU classifier identifies candidate ultrasound-responsive compounds without requiring reliable negative labels. We then validate the AI-based predictions in physiologically relevant U-87 MG glioblastoma spheroids that reproduce key TME features, including spatial heterogeneity and a hypoxic core. The NAM identifies two FDA-approved drugs, carboplatin (advanced ovarian cancer) and memantine hydrochloride (Alzheimer’s disease), as effective ultrasound-responsive agents. In 3D spheroids, combining low-intensity pulsed ultrasound with either drug significantly reduces viability compared with drug-only controls, and both combinations outperform temozolomide (TMZ), the current standard chemotherapeutic. Time-resolved responses reveal distinct kinetics: memantine produces strong early cytotoxicity (24 h) enhanced by ultrasound, whereas carboplatin shows delayed but pronounced cytotoxicity (72 h), also improved by ultrasound. Together, these results establish an integrated computational–experimental NAM that enables rapid repurposing of approved drugs as SDT sensitizers and provides a scalable framework for advancing GBM therapeutic discovery while reducing reliance on animal studies.